SmartClot Personalized platform for the combined evaluation of platelet and coa...
SmartClot Personalized platform for the combined evaluation of platelet and coagulation factor in haemostasis or during antithrombbotic therapy
Today there is a big concern about cardiovascular diseases (CVD); because each year, it causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. With almost 49 million people living with cardiovascula...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
VETEX
Deep Vein Thrombosis A Paradigm Change in Treatment through...
4M€
Cerrado
TAPAS
TArgeting Platelet Adhesion receptors in thrombosiS
4M€
Cerrado
CoaguPOC
SMART POINT OF CARE DEVICE FOR SELF PATIENT MANAGEMENT OF TH...
71K€
Cerrado
PRESTIGE-AF
PREvention of STroke in Intracerebral haemorrhaGE survivors...
7M€
Cerrado
ThromboSLE
Accurate assessment of thrombosis risk in systemic lupus ery...
71K€
Cerrado
POC products
A novel microfluid based modular system to address POC chall...
71K€
Cerrado
Información proyecto Smart Clot
Duración del proyecto: 3 meses
Fecha Inicio: 2018-08-02
Fecha Fin: 2018-11-30
Líder del proyecto
SEDICIDODICI SRL
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Today there is a big concern about cardiovascular diseases (CVD); because each year, it causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. With almost 49 million people living with cardiovascular disease in the EU, these problems have a huge impact on public health and on health and economic resources, with a total cost of € 2.10 billion/year. Unfortunately, over the last 25 years the number of cardiovascular diseases cases has increased in Europe. The current medical devices monitor just platelet aggregation or coagulation providing inaccurate estimations and in consequence observing insufficient therapy in thrombosis treatment or excessive therapy dosage in bleeding cases in individual patients. In response, we at SEDICIDODICI have developed, SMART CLOT, a cutting-edge technology for the combined evaluation of coagulation and platelet function for monitoring i) haemostasis (process which causes bleeding to stop, keeping the blood within a damaged blood vessel) as diagnosis tool and ii) antithrombotic treatment to control patients with diseases such as cardiovascular diseases, hypertension, thrombosis, diabetes, pulmonary embolism. It is a user-friendly, automated and real-time platform that provides qualitative/quantitative information based on an instrument and an array of multifunctional flow cartridges designed to interrogate specific pathways of both coagulation and platelet activation under relevant arterial and venous flow conditions. Before reaching market maturity we need in Phase 1 to run a Feasibility Study that helps us organise technical, commercial and financial plan of the project. Finally, SMART CLOT will bring an effective platform for the diagnosis and antithrombotic treatment. SEDICIDODICI will concentrate on the growth of SMART CLOT and in 5 years from launch we expect to earn € 22.3 million in profits, 24 new people and a ROI of 6.08 per euro invested.